ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY 2026 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 8.830-9.340 for the period, compared to the consensus earnings per share estimate of 7.900. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.0 billion.

Analyst Upgrades and Downgrades

ANIP has been the subject of several research reports. Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Barclays initiated coverage on ANI Pharmaceuticals in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 price objective on the stock. Finally, Guggenheim lifted their price objective on ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. Six equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $103.43.

ANI Pharmaceuticals Stock Performance

ANI Pharmaceuticals stock opened at $76.10 on Wednesday. The stock has a fifty day moving average price of $79.99 and a 200 day moving average price of $86.18. ANI Pharmaceuticals has a 52 week low of $56.71 and a 52 week high of $99.50. The firm has a market capitalization of $1.71 billion, a P/E ratio of 22.65 and a beta of 0.52. The company has a current ratio of 2.71, a quick ratio of 2.19 and a debt-to-equity ratio of 1.11.

Insider Activity at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 500 shares of the company’s stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $84.33, for a total transaction of $42,165.00. Following the completion of the sale, the vice president directly owned 74,374 shares in the company, valued at $6,271,959.42. This represents a 0.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Renee P. Tannenbaum sold 1,800 shares of the stock in a transaction on Friday, December 5th. The stock was sold at an average price of $81.15, for a total value of $146,070.00. Following the completion of the transaction, the director directly owned 25,157 shares in the company, valued at $2,041,490.55. This trade represents a 6.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 13,459 shares of company stock valued at $1,066,611 over the last three months. Insiders own 12.70% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of ANIP. Advisors Asset Management Inc. acquired a new stake in ANI Pharmaceuticals during the 1st quarter worth approximately $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in ANI Pharmaceuticals by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock worth $736,000 after buying an additional 470 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in ANI Pharmaceuticals by 0.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock worth $3,235,000 after buying an additional 423 shares during the period. Jane Street Group LLC purchased a new position in shares of ANI Pharmaceuticals in the 1st quarter valued at $2,706,000. Finally, Norges Bank acquired a new position in shares of ANI Pharmaceuticals during the 2nd quarter valued at $625,000. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.